The authoritative source for research information and outputs is Elsevier Scopus, with researcher profile verification from the Deanship of Scientific Research.
المخرجات
Research outputs
Articles, reviews, conference papers and book chapters, indexed by DOI and linked to University researchers.
Polynucleotides (PNs) and polydeoxyribonucleotides (PDRNs) are increasingly used in regenerative dermatology; however, randomized evidence across skin rejuvenation, scar prevention, and wound healing has not been comprehensively synthesized. This systematic review evaluated randomized clinical trials investigating PN- and PDRN-based interventions in these indications. PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched through January 2026. Seven randomized trials involving 183 participants met the inclusion criteria. Four studies evaluated skin rejuvenation, one postoperative scar prevention, and two wound-healing applications. Across studies, PN and PDRN therapies improved wrinkle-related outcomes, scar quality, wound-healing metrics, and patient-reported satisfaction. The most consistent benefits were observed in wound-healing settings, where PDRN accelerated re-epithelialization and shortened healing time compared with controls. No serious treatment-related adverse events were reported. Although findings support the regenerative potential of PN- and PDRN-based therapies across multiple dermatologic applications, the evidence base remains limited by small sample sizes, heterogeneous treatment protocols, and variable outcome measures. Larger, adequately powered randomized trials are needed to establish optimal clinical indications and treatment strategies.
Adhesive small bowel obstruction (aSBO) is a common cause of emergency surgical admission, and the optimal initial management between early surgery and conservative non-operative management (NOM) remains debated, particularly regarding recurrence and short-term safety. This systematic review aimed to evaluate short- and long-term outcomes of early operative management compared with conservative treatment for aSBO in adult and paediatric populations. A systematic search of MEDLINE, Embase, Scopus, and Cochrane CENTRAL was conducted from inception to 2025 in accordance with PRISMA guidelines. Nine studies were included. In stable adults, NOM was generally safe with comparable short-term complication and mortality rates to early surgery; however, prolonged delays following NOM failure were associated with increased morbidity and bowel resection. Long-term outcomes consistently favoured early operative management, demonstrating a 40-60% relative reduction in recurrence. Water-soluble contrast protocols improved diagnostic accuracy and NOM success, while specific radiological findings predicted failure. In paediatric patients, NOM was effective in many cases, but infants under one year of age had a higher likelihood of requiring surgery, and delays beyond 48 hours increased bowel resection rates. Overall, NOM is safe for selected patients, but early surgery offers superior long-term recurrence outcomes.
adhesive small bowel obstructionearly surgical interventionconservative treatmentrecurrence
Botulinum toxin type A (BoNT-A) injections have a well-known cosmetic outcome and safety profile in a variety of medical conditions. Recent studies have shown promising results for possible use in treating erythematotelangiectatic rosacea (ETR). This systematic review aimed to evaluate the efficacy and safety of BoNT-A injections in patients with ETR. A systematic search was conducted across multiple databases to identify relevant studies. Eligible articles were randomized controlled trials (RCTs) that investigated BoNT-A injections in adults diagnosed with ETR. Studies involving other rosacea subtypes, lacking a comparative group, or combining BoNT-A with other interventions without isolating its effects were excluded. Three RCTs met the inclusion criteria. Both parallel-group and split-face analyses demonstrated that BoNT-A injections significantly reduced facial erythema and flushing, resulting in improved patient satisfaction. Across all studies, BoNT-A was well-tolerated, with adverse events being mild, transient, and self-limited. However, the evidence remains limited by the small sample sizes, suboptimal study designs, and short follow-up durations. BoNT-A injections show promising efficacy and safety in the treatment of ETR. However, larger, well-designed randomized trials with longer follow-up durations are required to confirm its therapeutic role and establish standardized treatment protocols.
botulinum toxin type Aerythematotelangiectatic rosaceafacial erythemaflushing
Melasma is a chronic acquired hyperpigmentation disorder that often exerts a psychosocial burden on affected individuals. Although laser- and light-based therapies are pivotal third-line interventions for recalcitrant cases, clinical consensus regarding their comparative efficacy and long-term safety remains inconsistent. This systematic review and meta-analysis aimed to evaluate and synthesize evidence from randomized controlled trials (RCTs) on the efficacy and safety of various laser-based therapies for melasma. A literature search was performed using PubMed, Excerpta Medica Database (EMBASE), Cochrane Library, and Web of Science databases from inception to January 2026. RCTs and split-face comparative studies evaluating laser therapies versus placebo, topical agents, or alternative laser modalities were included. Data synthesis was performed using a random-effects model with Hartung-Knapp adjustment. The primary outcome was the mean difference (MD) in the reduction of the Melasma Area and Severity Index (MASI) score. The certainty of evidence was appraised using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Fifty-two studies, involving 1,058 participants, met the inclusion criteria. The overall pooled analysis showed a trend toward clinical improvement that was not statistically significant (MD: 0.70; 95% CI: -0.55, 1.95; p = 0.2682). Subgroup analysis by laser technology revealed that low-fluence Q-switched Nd:YAG (QSNY) (1064 nm) lasers provided a statistically significant reduction in melasma severity (MD 1.47; 95% CI: 0.08 to 2.85, p < 0.05), while picosecond lasers (MD -0.11; 95% CI: -0.79 to 0.57) and fractional lasers (MD 0.94; 95% CI: -0.84 to 2.71) did not significantly outperform control groups. Statistical heterogeneity was high across the evidence (I² = 96.2%). The overall certainty of evidence for the primary outcome was very low because of the lack of blinding and the high inconsistency. No serious adverse events were reported, although minor complications, such as transient erythema and localized burning, were common. Low-fluence QSNY laser therapy is an effective adjunctive modality for melasma management. However, due to high recurrence rates and variability in outcomes, it should be integrated into a multi-modal approach alongside strict photoprotection and topical depigmenting agents. Future research should prioritize the long-term follow-up and standardization of laser parameters across different skin phenotypes.
Type 2 diabetes mellitus (T2DM) increases the risk of cardiovascular morbidity and end-stage renal disease. Renin-angiotensin-aldosterone system (RAAS) inhibitors, specifically angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are standard therapies for organ protection. However, uncertainty remains regarding their comparative efficacy and the safety of combination therapy. This systematic review and meta-analysis aimed to compare the efficacy of ACEIs versus ARBs in reducing cardiovascular and renal events in patients with T2DM and to assess the safety of dual blockade. PubMed, EMBASE, and Cochrane databases were searched for randomized controlled trials (RCTs) published up to 2025 comparing ACEIs, ARBs, or their combination against placebo or active controls in T2DM patients. The primary outcome was a composite of cardiovascular death, myocardial infarction, stroke, and renal failure. Methodological quality was assessed using the Cochrane Risk of Bias 2 tool. Data were synthesized using frequentist pairwise and Bayesian network meta-analyses. Heterogeneity was explored via meta-regression, and trial sequential analysis (TSA) was used to assess the sufficiency of evidence. In total, 16 RCTs involving 47,406 participants were included. In pairwise analysis, both ACEIs (risk ratio (RR) = 0.87, 95% confidence interval (CI) = 0.81-0.94) and ARBs (RR = 0.90, 95% CI = 0.83-0.98) significantly reduced the risk of the primary composite endpoint compared to control. Network meta-analysis showed no statistically significant difference between ACEIs and ARBs (RR = 0.98, 95% CI = 0.88-1.09). Although ACEIs ranked slightly higher in probability for reducing all-cause mortality (surface under the cumulative ranking = 78% vs. 65%), this difference was not statistically significant. Dual blockade (ACEI + ARB) increased the risk of hyperkalemia (RR = 2.8) and acute kidney injury (RR = 1.7) without improving efficacy. Meta-regression identified baseline systolic blood pressure as a significant modifier of treatment benefit (p = 0.04). TSA indicated that the evidence for the RAAS blockade's benefit is conclusive. ACEIs and ARBs exhibit comparable efficacy in preventing cardiovascular and renal events in patients with T2DM, with a marginal mortality benefit favoring ACEIs. Dual blockade is associated with increased harm and is not recommended. Monotherapy with either agent remains the preferred strategy for organ protection.
ACE inhibitorsangiotensin receptor blockerstype 2 diabetesrenin-angiotensin-aldosterone system blockade
Background Thrombocytopenia is a common hematological disorder encountered in clinical practice. To improve diagnostic efficiency and patient outcomes, it is important to understand its frequent clinical manifestations and predominant etiologies in different healthcare settings. This study aimed to describe the typical clinical presentations and underlying causes of thrombocytopenia among patients at a tertiary care hospital in the Kingdom of Saudi Arabia. Study design A single-center, retrospective cross-sectional study. Materials and methods Patients with thrombocytopenia (platelet count < 150,000/microL) admitted between January and December 2022 were included. Patients with pseudothrombocytopenia were excluded. Demographic, clinical, and laboratory data were collected through manual review of electronic medical records. Etiologies were recorded, and statistical analysis was performed using Stata software. Here and throughout, n denotes the number of patients contributing data to a given comparison, and N denotes the total cohort (N = 114). Where applicable, denominators were adjusted for missing data. Results Of 114 patients, 73 (64.04%) were male. The mean age was 40.80 ± 15.93 years, and the mean length of hospital stay was 11.83 ± 15.73 days. The mean platelet count was 51,480 ± 39,690/microL. Mild thrombocytopenia was observed in 19 (16.67%) patients, moderate in 31 (27.19%), and severe in 64 (54.14%). Infection was the most common etiology (n = 48, 42.11%), with Plasmodium species accounting for the largest number of cases (n = 25). Bleeding manifestations were observed in 72 (63.07%) patients, most commonly epistaxis (n = 16, 14.04%), ecchymosis (n = 13, 11.4%), and petechiae (n = 9, 7.89%). Patients with bleeding, particularly petechiae, ecchymosis, epistaxis, and gum bleeding, had significantly lower platelet counts than those without bleeding symptoms. Conclusion Infections were the predominant cause of thrombocytopenia in this cohort. Lower platelet counts were significantly associated with bleeding manifestations, particularly epistaxis, emphasizing the need for early recognition and appropriate clinical management.
Background Parental attitudes toward childhood vaccination play a critical role in vaccine uptake. Several factors can influence parental attitudes regarding vaccination. This study aimed to assess parental attitudes toward childhood vaccination in Riyadh, Saudi Arabia, and examine the influence of sociodemographic factors. Methodology A cross-sectional study was conducted among parents residing in Riyadh using an online, self-administered questionnaire distributed via social media platforms. The survey instrument was based on the Vaccine Attitudes Examination scale and consisted of 11 Likert-scale items. Data were analyzed using SPSS version 28. Results A total of 469 parents participated. Most respondents were female (n = 286, 61.0%), aged 25-44 years (n = 257, 54.8%), married (n = 402, 85.7%), and held a bachelor's degree (n = 267, 56.9%). Positive perceptions of vaccination were common, as 58.5% (n = 274) agreed or strongly agreed that they felt safe after vaccination, and 65.7% (n = 308) agreed or strongly agreed that vaccines prevent serious infectious diseases. Most participants also valued reliable information sources, with 81.2% (n = 381) agreeing or strongly agreeing that accurate information supports informed decisions. However, concerns persisted regarding unforeseen side effects and beliefs favoring natural immunity over vaccination. Overall, most participants demonstrated neutral attitudes (n = 348, 74.2%), followed by negative attitudes (n = 83, 17.7%) and positive attitudes (n = 38, 8.1%). Gender (p = 0.022) and employment status (p = 0.032) were significantly associated with attitudes. In multivariable analysis, female gender (odds ratio (OR) = 2.113, 95% confidence interval (CI) = 1.227-3.640, p = 0.007), larger family size (OR = 1.538, 95% CI = 1.043-2.269, p = 0.030), and employment status (OR = 1.299, 95% CI = 1.005-1.680, p = 0.046) significantly predicted negative attitudes. Conclusions Most parents in Riyadh demonstrated neutral attitudes toward childhood vaccination, while nearly one in five showed negative attitudes. Targeted educational strategies addressing safety concerns and misinformation may help strengthen vaccine confidence among parents.
Fibromyalgia causes symptoms like chronic widespread pain, fatigue, and cognitive difficulties, often alongside depression and chronic pain, complicating treatment. While selective serotonin reuptake inhibitors (SSRIs) are prescribed for fibromyalgia-related depression and pain, their effectiveness is unclear. This systematic review and meta-analysis evaluated SSRI efficacy in fibromyalgia patients with comorbid depression and chronic pain. This systematic review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) and conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. We searched PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, Ovid, and Google Scholar. We included randomized controlled trials (RCTs) using formal fibromyalgia criteria and reporting depression or pain outcomes. Non-RCTs, studies with non-adults, or non-SSRI comparisons without isolating SSRI effects were excluded. The Cochrane risk-of-bias tool for randomized trials (RoB-2) was used to assess the risk of bias in this study. Four reviewers independently screened titles and abstracts; four assessed full-texts with disagreements resolved by a senior reviewer. Outcome data were converted to mean change scores from baseline where not directly reported. The standardized mean difference (SMD) was used for the meta-analysis to pool data across different scales. Nine RCTs (n = 461 participants, predominantly female, mean ages across studies ranged from 32.7 to 52.9 years) were analyzed. Compared to placebo, SSRIs significantly reduced pain (eight RCTs, n = 421; SMD -0.53, 95% confidence interval (CI): -0.92 to -0.14, p = 0.007) and improved depression (six RCTs, n = 265; SMD -0.67, 95% CI: -1.14 to -0.20, p = 0.005). SSRIs also significantly improved quality of life (QOL) versus placebo (five RCTs, n = 301; SMD -0.30, 95% CI: -0.55 to -0.04, p = 0.02). Compared to other non-pharmacological interventions (acupuncture and aerobic exercise), SSRIs showed non-significant improvement in depression (two RCTs, n = 70; SMD -0.39, 95% CI: -1.32 to 0.54, p = 0.41). Common side effects included gastrointestinal issues, dry mouth, sedation, sexual dysfunction, and headaches; SSRI groups reported more adverse events and higher dropout rates. SSRIs showed statistically significant benefits for pain, depression, and QOL in fibromyalgia compared to placebo. However, the overall evidence quality was found to be very low to low due to heterogeneity and risk of bias. Future RCT designs should adhere to a strict methodology in order to strengthen the available evidence on the efficacy of SSRIs in treating fibromyalgia.
Zinc is a vital micronutrient that plays a role in many bodily functions, such as controlling the immune system, making proteins, and breaking down cells.Zinc deficiency is commonly acknowledged in postbariatric patients; however, its manifestation as isolated myopathy without typical dermatological signs is rare and may impede timely diagnosis.We report the case of a 49-year-old woman who presented with a five-month history of progressive generalized fatigue and proximal muscle weakness, resulting in a significant impairment of her activities of daily living.Her past medical history was significant for laparoscopic sleeve gastrectomy five years ago with reported compliance with routine multivitamin supplementation.On clinical examination, the muscle strength was decreased (4/5) without sensory deficits or cutaneous abnormalities.The initial laboratory work-up, including hematologic, metabolic, endocrine, and autoimmune studies, was essentially unremarkable except for an elevated erythrocyte sedimentation rate.Further work-up for trace elements revealed a significantly low serum zinc level with other minerals within normal limits.A diagnosis of myopathy due to severe zinc deficiency was made.The patient received oral zinc supplementation, resulting in complete clinical recovery and normalization of zinc levels within four months.This case demonstrates a unique manifestation of zinc deficiency presenting as isolated proximal myopathy in a post-sleeve gastrectomy patient, years after surgery and without classical features.It stresses the importance of evaluating trace element deficiencies in the differential diagnosis of unexplained neuromuscular symptoms and supports the need for long-term nutritional monitoring after bariatric procedures.
zinc deficiencysleeve gastrectomybariatric surgery complicationsmuscle weakness
Fractional carbon dioxide (FCO₂) laser-assisted topical therapy has been investigated to enhance drug delivery in nail psoriasis, but improvement from baseline does not establish whether laser pretreatment provides additional clinical benefit.This systematic review evaluated the comparative efficacy, safety, tolerability, and durability of FCO₂-assisted topical therapy.PubMed/MEDLINE, Scopus, and Web of Science were searched from inception through September 18, 2026.Comparative controlled studies were eligible, and risk of bias was assessed using the Cochrane RoB 2 tool.Five studies involving 134 participants were included.Three compared FCO₂-assisted topical therapy with the same topical agent alone, one compared two FCO₂-assisted topical regimens, and one compared laser-assisted topical corticosteroid therapy with intralesional corticosteroid treatment.Although nail severity improved over time across studies, direct comparative effects were inconsistent and varied by topical agent, comparator, and assessment time.Between-treatment advantages were observed in selected tazarotene and methotrexate comparisons, whereas other comparisons showed no clear incremental benefit.Laser-assisted corticosteroid treatment achieved broadly comparable short-term outcomes to intralesional therapy with less procedural pain and greater patient satisfaction.Four of five principal efficacy results were at high risk of bias, and one raised some concerns.Meta-analysis was not appropriate because of substantial heterogeneity.Current evidence does not establish a consistent incremental efficacy advantage of laser assistance.More rigorous, adequately powered trials with appropriate paired analyses and standardized follow-up are needed before routine adjunctive use can be recommended.
nail psoriasisfractional CO2 lasertopical treatmentclinical outcomes
BackgroundThe increasing use of anti-diabetic drugs, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs), for weight loss has prompted concerns about public awareness, attitudes, and usage.In Saudi Arabia, a substantial proportion of adults have obesity or are overweight, highlighting the considerable burden of obesity.Meanwhile, the increasing use of GLP-1 RAs for weight management underscores the importance of assessing public knowledge and attitudes toward these medications. ObjectiveThe objective of this study is to assess knowledge, attitudes, and practices regarding antidiabetic medications used for weight loss among adult residents of Riyadh, Saudi Arabia. MethodsThe cross-sectional survey included 282 adult residents of Riyadh.A self-administered electronic questionnaire was sent using a non-probability convenience sampling method.The questionnaire evaluated sociodemographic variables, knowledge, attitudes, and practices about antidiabetic medicines used for weight loss.Data were analyzed using nonparametric tests, Spearman's ρ correlation, and multivariable linear and binary logistic regression analyses. ResultsOf the 282 participants, 70.9% were female and 68.4% were married.The median knowledge score was 15.0 (interquartile range (IQR), 12.0-18.0),and the median attitude score was 23.0 (IQR, 21.0-25.0).Knowledge and attitude scores showed a weak positive correlation (Spearman's ρ = 0.254, p < 0.001).Overall, 76 participants (27.0%) reported using antidiabetic medications for weight reduction, with Ozempic (55.3%) and Mounjaro (44.7%) being the most commonly used medications.Female gender was independently associated with higher knowledge scores, whereas non-medical occupation was associated with lower knowledge and attitude scores.Participants with chronic disease had higher odds of weight-loss medication use, whereas higher attitude scores were associated with lower odds of use. ConclusionAdults in Riyadh demonstrated important knowledge gaps regarding weight-loss medications.Knowledge and attitudes varied by occupation, while medication use was independently associated with chronic disease status and attitude scores, highlighting the need for evidence-based education and medically supervised use.
Erythema annulare centrifugum (EAC) is a rare reactive dermatosis that can be difficult to manage in persistent cases.A 54-year-old woman presented with pruritic, annular, and polycyclic plaques that subsequently extended to the neck, trunk, upper back, hands, lower legs, and feet.A skin biopsy supported the diagnosis of superficial EAC on clinicopathologic correlation.After limited improvement with topical therapies and oral prednisolone, she received four weekly doses of empiric oral fluconazole 150 mg without adverse effects.The eruption improved, and approximately five months after treatment discontinuation, she remained clear apart from residual post-inflammatory hyperpigmentation.The temporal association suggests a possible treatment response; however, the absence of pretreatment mycologic testing and the possibility of spontaneous remission limit causal interpretation.
Protracted bacterial bronchitis (PBB) is a treatable cause of chronic wet cough in children but is frequently missed.Unrecognized children often cycle through repeat asthma treatment, short antibiotic courses that do not address the infection, or open-ended reassurance without further evaluation.This review summarizes the clinical presentation, diagnostic criteria, differential diagnosis, treatment, and follow-up of PBB in children.We conducted a targeted narrative review (PubMed, through September 2026) of clinical trials, longitudinal studies, systematic reviews, and professional-society guidance, distinguishing evidence for antibiotic treatment from limited observational evidence linking recurrent PBB to bronchiectasis.Clinicians should suspect PBB in a child with a daily wet cough lasting more than four weeks and no findings indicating another cause.Resolution after an appropriate antibiotic course supports the diagnosis.Amoxicillinclavulanate remains the usual first-line treatment, typically for two weeks initially, with reassessment and selective extension to four weeks if the child has not cleared.Further investigation is warranted when symptoms persist despite adequate treatment, recurrence is frequent, or specific warning signs appear.In an otherwise typical, treatment-responsive case, bronchoscopy and chest computed tomography (CT) are not routine first steps.Management hinges on recognizing the wet-cough phenotype, giving an adequate therapeutic trial, confirming resolution, and investigating promptly when treatment fails.Antibiotics appear to improve cough resolution, but this rests on a small number of trials with limited certainty, and evidence that treatment itself prevents bronchiectasis remains thin.
Rifaximin, a minimally absorbed broad-spectrum oral antibiotic, is used to target gut dysbiosis in patients with irritable bowel syndrome (IBS).However, conflicting trial data and methodological heterogeneity necessitate an updated, rigorous synthesis of its efficacy and safety profile.We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing rifaximin with placebo in adult patients with IBS, adhering to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines.The primary outcome was global symptom relief at the end of the treatment.Data were pooled using inverse-variance random-effects models with Hartung-Knapp-Sidik-Jonkman (HKSJ) adjustment.Evidence robustness was evaluated using prediction intervals (PI), Trial Sequential Analysis (TSA), trim-and-fill algorithms for publication bias, and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology.Nine RCTs (yielding 10 randomized comparisons due to one trial's a priori stratification by small intestinal bacterial overgrowth status) were included in this review.For the primary outcome (eight comparisons, N=2,056), rifaximin significantly improved global symptom relief compared to placebo (RR 1.54, 95% CI 1.13 to 2.11; p=0.014), corresponding to a number needed to treat for benefit (NNTB) of 6.However, statistical heterogeneity was substantial (I 2 =59.5%), and the 95% PI crossed the line of no effect (0.89-2.67).The primary effect lost statistical significance upon the exclusion of high-risk-of-bias trials (RR 1.47, 95% CI 0.95-2.27)and after adjusting for publication bias using the trim-and-fill method (RR 1.37, 95% CI 0.93-2.01).The TSA indicated that the accrued information size remained inconclusive for a conservative 15% relative benefit.Rifaximin demonstrated no statistically detectable difference in adverse events compared to placebo, though this is accompanied by considerable uncertainty (Peto OR 0.89 (95% CI 0.65-1.22)).Rifaximin demonstrates a modest overall benefit for global IBS symptoms and an excellent safety profile; however, the certainty of evidence is very low.The apparent efficacy is highly fragile, driven largely by industry-funded trials, undermined by publication bias, and characterized by wide prediction intervals.Biomarker-guided stratification, such as testing for small intestinal bacterial overgrowth (SIBO), may be required to optimize patient selection in future independent trials.
Post-acne erythema (PAE) is a persistent acne sequela without an established standard treatment. This systematic review evaluated the comparative efficacy and safety of interventions tested in randomized trials. PubMed/MEDLINE, Scopus, and Web of Science were searched from inception through August 1, 2026. Randomized parallel-group and split-face trials reporting erythema outcomes were eligible. Risk of bias was assessed with the Cochrane Risk of Bias 2 (RoB 2) tool. Heterogeneity precluded meta-analysis, and available findings were synthesized narratively. Nine trials involving 301 participants contributed 11 pairwise comparisons. Against untreated or blank controls, favorable effects were reported for picosecond alexandrite laser, narrow-spectrum vascular intense pulsed light (IPL), and non-cross-linked hyaluronic acid mesotherapy. A 577-nm semiconductor laser showed interim instrumental benefit, but blinded assessors found no final between-side difference. In active-treatment and add-on comparisons, narrow-spectrum IPL was favored over broad-spectrum IPL, neodymium-doped yttrium aluminum garnet (Nd) laser added to low-dose isotretinoin was favored over isotretinoin alone, and 577-nm pro-yellow laser was favored over topical brimonidine. Botulinum toxin type A was favored over broadband light at the earliest assessment only. Fractional laser and pulsed dye laser did not differ significantly, while delicate pulsed light and Q-switched 1064-nm Nd laser showed no sustained difference at the final assessment. Adverse events were mild and transient, although pigmentation and blistering occurred with one broad-spectrum IPL protocol. Five trials had some concerns, and four had high overall risk of bias. Trials suggested potential benefits, but small samples, heterogeneity, short follow-up, and reporting limitations precluded identification of a preferred treatment. Larger, prospectively registered trials using blinded assessment and standardized outcomes are needed.